ÇáãÓÇÚÏ ÇáÔÎÕí ÇáÑÞãí

ãÔÇåÏÉ ÇáäÓÎÉ ßÇãáÉ : ÚÇÇÇÌá ÌÏÇð ( ÏæÇÁ íÓÈÈ ÝÔá ßáæí ) ÕæÑÉ



ÃÍãÏ Èä ÍãæÏÇáÚÑÇÏí
09-12-2006, 04:10 PM
ÇáÓáÇã Úáíßã







Êã äÞáå ááÃåãíÉ ÇáÞÕæì





åÐÇ ÇáÏæÇÁ ÇÍÏ ÂËÇÑå ÇáÌÇäÈíÉ ÇáÝÔá Çáßáæí ÇáÊÇã åÐÇ ÇáÏæÇÁ

æÃÔßÇáå ãä ãÓßäÇÊ ÇáÂáÇã ÇáÍÏíËÉ ÇáÅäÊÇÌ æÇáÊí áã íÌÑì ÚáíåÇ

ÏÑÇÓÇÊ ÊÃßíÏíÉ æãßËÝÉ æááÚáã åÐÇ ÇáÏæÇÁ áå ÝÞØ ÇÞá ãä ÓÊ Ãæ

ÓÈÚ ÓäæÇÊ ãä ÅäÊÇÌå æÊÌÇÑÈå æÅØáÇÞå ááÃÓæÇÞ , ÇÚÊÞÏ Çäå

ÃØáÞ ááÃÓæÇÞ Ýí ÇáÏæá ÇáäÇãíÉ ÝÞØ ßí íÚÑÝæÇ äÊÇÆÌ ÂËÇÑå

ÇáÌÇäÈíÉ íÚäí ÕÑäÇ ÍÞæá ÊÌÇÑÈ áÔÑßÇÊ ÇáÃÏæíÉ ÇáÃæÑæÈíÉ

æÇáÃãÑíßíÉ ÝÇáãÚÑæÝ åäÇß Ýí ÃæÑæÈÇ æÃãÑíßÇ ÎÇÕÉ Ãä ÇáÃÏæíÉ

æÇáãÖÇÏÇÊ ÇáÍíæíÉ æÇáãÓßäÇÊ ÇáÞæíÉ áÇ ÊÕÑÝ ÅáÇ ÊÍÊ ÑÞÇÈÉ

ÔÏíÏÉ ãä ÞÈá æÒÇÑÇÊ ÇáÕÍÉ æÇáÅÔÑÇÝ ÇáÔÏíÏ Úáì ÍÇáÇÊ

ÇáÚáÇÌ ÇáÎÇÕÉ ÇáÊí ÊÍÊÇÌ áãËá åÐå ÇáÃÏæíÉ


Be careful



ßá æÇÍÏ íÔíß Úáì ÃÏæíÊå æÃÏæíÉ Ãåáå ÎÕæÕÇ Çááí íÊÚÇáÌæä Ýí ÚíÇÏÉ ÇáãÓÇáß ÇáÈæáíå æÇáÑæãÇÊíÒã

æÇáÇÚÕÇÈ æÇáÚÙÇã

Celebrex Ýí ÏæÇÁ ÅÓãå

ÅßÊÔÝæÇ ÎØæÑÊå ÇáÔÏíÏå Úáì ÇáÍíÇå ÈÚÏ ãÇ ÓÈÈ äÒíÝ

ÈÇáÏãÇÛ áÚÏÉ ÃÔÎÇÕ æÌÇÁ ÊÚãíã ÝæÑí ÈÊÈáíÛ ÇáãÑÖì

Ýí ÇáÈíæÊ áæÞÝ ÅÓÊÎÏÇãå ÍÇáÇ .!!!

Çááåã Åäí ÈáÛÊ Çááåã ÝÅÔåÏ





http://www.9m.com/upload/11-9-2006/0.532011579962.gif

ÇáßÇÊÈ ÇáßÈíÑ ãæÓì ÚÈÏÇááå ÇáÈáæí( ÑÍãå Çááå )ÇáãáÞÈ ÈÑÇÚí ÇáÐáæá æäÝØæíå
09-12-2006, 04:14 PM
جزيت خيرا .. وبارك الله فيك .. يالغالي أحمد العرادي

دول العالم العاشر .. دائما محل تجارب للغرب ( المتمقرط ) في الأسلحه وفي الدواء أيضا ..
ولك تحياتي ..!!

ÑÖÇ ãÍãæÏ ÇáãÚíÞáí
09-12-2006, 05:38 PM
جزاك الله خير ..

ماقصرت

ÇáÜÜÝÜÜíÜÜÕÜÜá
09-12-2006, 08:23 PM
æÈÇÑß Çááå Ýíß

ÈäÊ ÇáäæÑ*
09-13-2006, 01:26 PM
http://www.9m.com/upload/11-9-2006/0.532011579962.gif


áßá ÚáÇÌ ÂËÇÑå ÇáÌÇäÈíÉ ÈÇáÊÃßíÏ æáßä ÊÎÊáÝ ÍÏÊåÇ ãä ÚáÇÌ áÂÎÑ ......
ÅÐÇð áäÌÚá ÇáÚáÇÌ ááÖÑæÑå æáÇäÓÑÝ Ýí ÇÓÊÎÏÇãå æÇáÐí åæ ÈÇáÏÑÌÉ ÇáÃæáì íÍÊÇÌ áÅÓÊÔÇÑå
ØÈíå ÊæÎíÇð áæÕÝÇÊ ÚÔæÇÆíå ãä ÇáÃÕÏÞÇÁ ÞÏ ÊæÑÏ ÇáãåÇáß ...
ÇáÏæÇÁ ãÓÊÍÖÑ ØÈí íÌÈ ÇáÍÐÑ ÚäÏ ÊÚÇØíå ÓæÇÁ ÈÌÑÚÇÊå ÇáãÞääå Ãæ ÇáÅäÊÙÇã ÈãæÇÚíÏå ...

ÈÇÑß Çááå Ýíß ÝÇÖáí æÌÒíÊ ÇáÎíÑ ÚäÜÜÜÜÜÜÜÜÜÜÜÜÜÇ ÌãíÚÇð .............æÏãÊ ÈÕÍÉ ò æÚÇÝíå ..


äææææææææææææææææææÑ :|for you|:

íÇÓÑ ÍãÏÇä ÇáãÞÈáí
09-13-2006, 02:28 PM
جزاك الله خير

ÓáãÇä ÇáÚÑÇÏí
09-14-2006, 04:00 AM
ÈÇÑß Çááå Ýíß Úáì åÐÇ ÇáÊäæíå ..

ÇÈä ÚÑÝå ÇáÑãæËí
09-14-2006, 04:24 PM
الله يجزاك خير

ÇáÚØÇ
09-14-2006, 10:45 PM
جزاك الله خير @

ãæÓì Èä ÑÈíÚ ÇáÈáæí
09-15-2006, 01:59 AM
È1

áÇ íÎÝì Úáì ÃÍÏ Ãä áßá ÏæÇÁ ÂËÇÑ ÌÇäÈíÉ ãåãÇ ßÇä

æ Úáì ÓÈíá ÇáãËÇá /
ÇáÇÓÈÑíä áå ÂËÇÑ Úáì ÇáãÚÏÉ æ íÓÈÈ ÞÑÍÉ ( Ýí ÍÇáÉ ÇáÅßËÇÑ ãäå ) æ ßÐÇ ÈÞíÉ ÇáãÓßäÇÊ ãËá ÇáÈÑæÝíä æ ÇáÝæáÊÇÑíä æ ÃíÖÇð íÓÈÈ ÇáÃÓÈÑíä ( ãÚ ÇáÇÓÊÎÏÇã ÇáßËíÑ áå ) íÓÈÈ äÒíÝÇð æ íÈØÆ ÇáÊÎËÑ Ýí ÇáÏã áÐÇ Ýåæ áÇ íÚØì ááãÑÃÉ ÇáÍÇãá ..


ßÐÇ ÝÅä ãä ÃÚÑÇÖ ÇáÈÇÑÓíÊÇãæá ( ÇáÈäÇÏæá ) ÇáÌÇäÈíÉ ÇáÊÃËíÑ ÇáÖÇÑ Úáì Çáßõáì æ ÇáÅÓÊÎÏÇã ÇáßËíÑ áå íÄËÑ Úáì Çáßõáì .

................


æ ÇáÏæÇÁ ÇáÐí äÍä ÈÕÏÏ ÇáÍÏíË Úäå íæÌÏ áå ÂËÇÑ ÌÇäÈíÉ ÊÊÖÍ Úä ÇáÅÓÊÎÏÇã ÇáßËíÑ Ãæ ÇáÚÔÇæÆí áå Ïæä ÅÓÊÔÇÑÉ ØÈíÉ

æ ÞÏ ÈÍËÊ Úä ÇáÏæÇÁ ÇáãÐßæÑ Ýí ÃÍÏ ÇáãæÇÞÚ ÇáãÎÕÕÉ ( ÅÏÇÑÉ ÇáÛÐÇÁ æ ÇáÏæÇÁ ÇáÃãÑíßíÉ )
http://www.fda.gov/cder/drug/infopage/celebrex/celebrex-ptsk.htm

ÝæÌÏÊ åÐå ÇáãÚáæãÇÊ Úäå

This is a summary of the most important information about Celebrex. For details, talk to your healthcare provider.

FDA ALERT-[4/7/2005]: Celebrex has been linked to an increased risk of serious cardiovascular (CV) events (such as heart attack or stroke) which appears to be a risk shared by all medicines called non-steroidal anti-inflammatory drugs (NSAIDs) (excluding aspirin). FDA has requested that the package insert (labeling) for all NSAIDs, including Celebrex, be revised to include a “boxed” or serious warning to highlight the potential increased risk of CV events, and the well known risk of serious, and potentially life-threatening, stomach bleeding. FDA has also requested that the package insert for all NSAIDs be revised to state that patients who have just had heart surgery should not take these medicines. (http://www.fda.gov/cder/drug/infopage/celebrex/celebrex-hcp.htm)
ÈÅÎÊÕÇÑ åäÇ íÊÍÏË Úä ÃÖÑÇÑ Úáì ÇáÞáÈ æ ÇáãÚÏÉ

What is Celebrex?
Celebrex is used to:


relieve symptoms of osteoarthritis (the arthritis caused by age-related “wear and tear” on bones and joints)

relieve symptoms of rheumatoid arthritis in adults

manage acute pain in adults (like the short term pain you can get after a dental or surgical operation)

treat painful menstrual cycles

reduce the number of colon and rectum growths (colorectal polyps) in patients with a disease called Familial Adenomatous Polyposis (FAP). FAP is an inherited disease in which the rectum and colon are covered with many polyps. Celebrex is used along with the usual care for FAP patients such as surgery and exams of the rectum and colon.

Who Should Not Take Celebrex?
Do not take Celebrex if you:


have had an allergic-type reaction to sulfa medicines.

have had asthma, hives or allergic-type reactions after taking aspirin or other NSAID (nonsteroidal anti-inflammatory drugs) medicines. If you have asthma, you may have aspirin-sensitive asthma. If an aspirin-sensitive asthmatic takes aspirin it can cause severe narrowing of the airway (bronchospasm), and even death. Since this type of reaction also has occurred after taking NSAIDs Celebrex should not be given to aspirin-sensitive patients.


Some examples of NSAIDs are ibuprofen (Motrin, Advil), naproxen (Naprosyn, Aleve), diclofenac (Voltaren, Cataflam), and ketoprofen (Orudis). You can ask your doctor or pharmacist for a complete list of these medications.


are pregnant, especially during your last 3 months

áÇ íÚØì Ýí ÍÇáÉ ÇáÍÓÇÓíÉ ááÏæÇÁ Ãæ ÇáÇÓÈÑíä Ãæ ÇáÑÈæ Ãæ ÇáÍÓÇÓíÉ áãÖÇÏÇÊ ÇáÃáã Ãæ ááÍÇãá
What are The Risks?
Celebrex and other NSAID medicines can cause serious problems such as:


Stomach ulcers that bleed. The chance of this serious problem increases the longer you take Celebrex, but it can also happen suddenly. Stop taking Celebrex and call your healthcare professional right away if you get a burning stomach pain, black bowel movements that look like tar, or vomit that looks like blood or coffee grounds.


Liver damage. Some of the warning signs of liver damage are nausea, vomiting, tiredness, loss of appetite, itching, yellow coloring of skin or eyes, “flu-like” symptoms and dark urine. If this happens, stop taking Celebrex and call your healthcare professional right away.


Kidney problems that include sudden kidney failure or worsening of kidney problems that you already have.


Fluid retention (holding of water in your body) and swelling. Fluid retention can be a serious problem if you have high blood pressure or heart failure.

áå ÂËÇÑ ÖÇÑÉ Úáì ÇáßÈÏ æ Çáßõáì æ ÞÑÍÉ æ ÅÍÊÈÇÓ ÇáãÇÁ Ýí ÇáÌÓã ããÇ ÞÏ íÄÏí Çáì ÊæÑã

In addition to the serious side effects listed above, some common, but less serious side effects with Celebrex may include:


headache

indigestion

upper respiratory tract infection (a "cold")

diarrhea

sinus inflammation

stomach pain

nausea

What Should I Tell My Healthcare Professional?
Tell your healthcare professional if you:


have heart problems or high blood pressure

have liver or kidney problems

have or had stomach ulcers or stomach bleeding

have asthma

are allergic to aspirin or other NSAID medicines

are trying to become pregnant, are already pregnant, or are breast-feeding

Are There Any Interactions With Drugs or Foods?
Tell your healthcare professional about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Some medicines may affect how Celebrex works or Celebrex may affect how your other medicines work. Your healthcare professional may have to adjust your dose or watch you closely if you take any of the following medications:


certain blood pressure medicines called ACE inhibitors

furosemide

fluconazole or ketoconazole

phenytoin

warfarin

aspirin

Celebrex FDA Approved 1998
Patient Information Sheet Revised 04/2005

ãæÓì Èä ÑÈíÚ ÇáÈáæí
09-15-2006, 02:06 AM
ãÚáæãÇÊ ÃÎÑì Úä ÇáÏæÇÁ

ÕÍÉ ÚÇãÉ ÊäÇæá ÇáãÓßäÇÊ ãä Ïæä ÑÃí ÇáØÈíÈ íáÍÞ ÖÑÑÇð http://albayan.ae/servlet/Satellite?blobcol=urllowres&blobheader=image%2Fjpeg&blobkey=id&blobnocache=false&blobtable=CImage&blobwhere=1139465670674&ssbinary=true íÄßÏ ÇáÃØÈÇÁ Úáì ÃåãíÉ ÚáÇÌ ÇáÃáã æÊËÈíØå ÈÕæÑÉ ÊÖÝí ÇáÓÚÇÏÉ Úáì ÞáÈ ÇáãÑíÖ æÊÊíÍ áå ÇáÝÑÕÉ ßí íæÇÌå äÔÇØ ÇáÍíÇÉ Çáíæãí Ïæä ãÚÇäÇÉ.

ÇáÏßÊæÑ ãÍãÏ ÚÒÇã ÞíÇÓå ÃÎÕÇÆí ÃãÑÇÖ ÇáåÖã æÇáßÈÏ Ýí ÏÈí ÊÍÏË Úä ãÔßáÇÊ ÇáÃáã æÚáÇÌå æÇáÊÃËíÑÇÊ ÇáÌÇäÈíÉ ááãÓßäÇÊ æÞÇá : «ÇáãÌÇá Çáíæãí áÊÎÕÕí åæ ãæÇÌåÉ ÇáÊÃËíÑÇÊ ÇáÌÇäÈíÉ ááãÓßäÇÊ¡ áÃä ßá ãÓßä áå ÊÃËíÑ ÌÇäÈí Úáì ÌåÇÒ ÇáåÖã. æáå ÃíÖÇ ÊÃËíÑÇÊ ÌÇäÈíÉ Úáì ÇáÃãÚÇÁ ÇáÏÞíÞÉ æÇáÅËäí ÚÔÑ æÇáÞæáæä ÝÖáÇ Úä ÊÃËíÑÇÊ ÌÇäÈíÉ Úáì ÇáßÈÏ».

æíÚÏ ÇáÓíáíÈÑíßÓ¡ æåæ ÃÍÏ ÇáÃÏæíÉ ÇáÍÏíËÉ¡ ÇáÊí íØáÞ ÚáíåÇ ãËÈØÇÊ ÇáÜ COX-2¡ æÊÞæã ÈÊËÈíØ ÃäæÇÚ ãä ÇáÃäÒíãÇÊ ÇáÊí ÊÖÇÚÝ ÇáÇáÊåÇÈÇÊ æÊÒíÏ ÇáÃáã Ýí ÇáæÞÊ ÐÇÊå. æíÃÊí ÇáÓíáíÈÑíßÓ áÊËÈíØåÇ æÊÞáíá ÇáÇáÊåÇÈÇÊ æíÚãá Úáì ÊÓßíä ÇáÃáã. íËÈØ åÐÇ ÇáäæÚ ãä ÇáÃÏæíÉ ÇáãÓÊÞÈáÇÊ ÇáãæÌæÏÉ Úáì ãÓÊæì ÇáÎáíÉ¡

æÈÇáØÈÚ ÇáãæÌæÏÉ Ýí ÇáÕÝíÍÇÊ ÇáÏãæíÉ ÇáãæÌæÏÉ Ýí ßá ÇáÃãÇßä ÇáÊí ÊÊÚÑÖ ááÇáÊåÇÈÇÊ. æáßä ÊäÔíØ ÇáãÓÊÞÈáÇÊ ÇáÜ COX-2 áåÇ ãÓÇæÆ æãÍÇÓä Ýí ÇáæÞÊ ÐÇÊå Ýåí íãßä Ãä ÊÓÇÚÏ ÇáÕÝíÍÇÊ ÇáÏãæíÉ Úáì ÚãáíÉ ÇáÊãíÚ ÇááÇÒã ááÏã. æíÞæã ÇáÚÞÇÑ ÓíáíÈÑíßÓ Ãæ ãÔÊÞÇÊå ÈÏæÑ ÇáãËÈØ æíÞÖí Úáì ÇáÃáã¡ æåæ ÇáåÏÝ ãä ÊäÇæá ÇáÏæÇÁ æÇáÝÇÆÏÉ ãä ßá ãÇ ÐßÑäÇå ÂäÝÇ åæ ÊÎáíÕ ÇáãÑíÖ ãä ÇáÃáã. æåäÇß ÃíÖÇ ãÓßäÇÊ ÃÎÑì ãËá ãÔÊÞÇÊ ÇáãæÑÝíä æÇáÈÇÑÇÓíÊÇãæá.

ãÌáÉ «ÇáÕÍÉ ÃæáÇ» ÇáÊÞÊ ÇáÏßÊæÑ ãÍãÏ ÚÒÇã ÞíÇÓå ÃÎÕÇÆí ÃãÑÇÖ ÇáåÖã æÇáßÈÏ Ýí ÏÈí æÃáÞì ÇáãÒíÏ ãä ÇáÖæÁ Úáì ÎæÇÕ ÇáÃÏæíÉ ÇáãËÈØÉ æÊÍÏË Úáì ãÖÇÚÝÇÊ ÈÚÖåÇ Úáì ÇáÌåÇÒ ÇáåÖãí æÚáì ÇáÎÕæÕ Úáì ÇáßÈÏ.

- åá ÅãßÇäíÉ ÇáÊÎáÕ ãä ÇáÃáã ÚãáíÉ ÕÚÈÉ Ãæ ãÚÞÏÉ æÊÍÊÇÌ Åáì ØÈíÈ ÞÇÏÑ Úáì ÚáÇÌ ÇáÃáã¿

Ü åäÇß ÃØÈÇÁ ÃÎÕÇÆíæä æÙíÝÊåã ãÚÇáÌÉ ÇáÃáã¡ ÝÇáÃáã ÏÇÆãÇ ãæÌÚ æíÓÈÈ ááãÑíÖ ÅÑåÇÞÇ ÔÏíÏÇ æãÚÇäÇÉ ÛíÑ ãÍÏÏÉ. æíäÈÛí Úáì ÇáØÈíÈ ÇáãÚÇáÌ Ãä ÊÊæÝÑ áÏíå ÇáÏÑÇíÉ Ýí ÚáÇÌ ßá Ãáã¡ æÇáÃáã ÇáãÒãä íäÈÛí Úáì ØÈíÈ ÚáÇÌ ÇáÂã ÇáãÒãäÉ Ãä íÚÇáÌå.

- åá åäÇß ÃÏæíÉ ÊÄÏí Åáì ãÖÇÚÝÇÊ ÝÊÍæá ÇáÃáã ÇáãÄÞÊ Åáì Ãáã ãÒãä¿

Ü áíÓÊ åäÇß ãËá Êáß ÇáÃÏæíÉ¡ ÝäÍä ÚäÏãÇ äËÈØ ÇáÃáã ÓæÇÁ ßÇä ÍÇÏÇ Ãæ ãÒãäÇ áÇ íÊÍæá ÇáÃáã ãä Ãáã ÍÇÏ Åáì ãÒãä¡ áÃä ÇáÃáã ÇáÍÇÏ ÍÊì íÊÍæá Åáì Ãáã ãÒãä íäÈÛí Ãä íßæä Ýíå ãäÈåÇÊ ÊÄÏí Åáì ÊäÔíØ ÇáãÓÊÞÈáÇÊ ÇáãÓÄæáÉ Úä ÇáÃáã. ÃãÇ ÚäÏãÇ äÞæã ÈÊËÈíØ ÇáãÓÊÞÈáÇÊ íäÊåí ÇáÃáã. æíãßä åäÇ ÊÕäíÝ ÇáãÓßäÇÊ Åáì äæÚíä: ÃÏæíÉ ãÖÇÏÉ ÇáÇáÊåÇÈÇÊ ÛíÑ ÇáÓÊíÑæÆíÏíÉ (NSAIDs) æåí ÊäÊãí áÌíáíä ãä ÇáÃÏæíÉ ÇáãËÈØÉ ãäåÇ ÍÏíËÉ æÇáÃÎÑì ÞÏíãÉ.

æíÚÏ ÇáÓíáíÈÑíßÓ ãä ÇáãåÏÆÇÊ ÇáÍÏíËÉ æÈÚÏ ÏÑÇÓÉ ÊÈíä Ãä ÇáÏæÇÁ ÇáÍÏíË áå ããíÒÇÊ ÊÝæÞ ÇáÞÏíã ÍíË æÌÏ ÈÇÍËæä Ãä ÇáÌÏíÏ ÊÎáÕ ãä 50% ãä ÇáãÖÇÚÝÇÊ ÇáÊí ßÇäÊ ãæÌæÏÉ Ýí ÇáäæÚ ÇáÞÏíã. æáÇ ÊÞÊÕÑ ÝÇÆÏÉ ÇáÓíáíÈÑíßÓ Úáì ÚáÇÌ ÇáÂáÇã ÇáãÚÏÉ Ýåæ íÚÇáÌ ÃíÖÇ ÇáÂáÇã ÇáÎÇÑÌíÉ æÇáÂáÇã ÇáØÑÝíÉ ãËá ÇáÕÏÇÚ æÇáÂã ÇáÃØÑÇÝ æÇáÙåÑ æíãßä ÇÓÊÎÏÇãå ÃíÖÇ Ýí ÚáÇÌ ÇáÌíæÈ ÇáÃäÝíÉ æáßä ÈÚÏ ÇÓÊÔÇÑÉ ÇáØÈíÈ. æíÚäí Ðáß ãä ßÇä íÚÇäí ãä Ãáã Ýí ÇáÕÏÑ Ãæ ÇáÈØä íäÈÛí Úáíå ÃáÇ íÊäÇæá ÇáÓíáíÈÑíßÓ.

æíäÈÛí Úáì ÇáØÈíÈ ÇáÌíÏ Ãä íÓÃá ÇáãÑíÖ¡ ÞÈá ÅÚØÇÆå ÇáÓíáíÈÑíßÓ¡ ãÇ ÅÐÇ ßÇä íÚÇäí ãä ÞÑÍÉ ãÚÏíÉ Ãæ ãÚæíÉ Ãæ ÓÈÞ áå Ãä ÊÚÑÖ áäÒÝ Ýí ÇáãÚÏÉ Ãæ áÊÌáØ. æäáÇÍÙ Ãä åäÇß ãÓßäÇ ÈÓíØÇ ãËá ÇáÃÓÈÑíä ÇáÐí áå ãäÇÝÚ æÝí ÇáæÞÊ äÝÓå áå ÖÑÑ Úáì Ãí ÔÎÕ íÚÇäí ãä ãÔßáÇÊ Ýí ÇáãÚÏÉ æíãßä Ãä íÄÏí ÇÓÊÎÏÇã ÇáÃÓÈÑíä Ýí ãËá åÐå ÇáÍÇáÇÊ Åáì äÒÝ ãÊæÇÕá Ýí ÇáãÚÏÉ. æÚáì Ðáß Úáì ÇáØÈíÈ ÇáãÚÇáÌ ÏÇÆãÇ Ãä íÓÃá ãÑíÖå Úä ÃíÉ ÃãÑÇÖ ÞÏ íßæä ãÕÇÈÇ ÈåÇ ãËá ÊÞÑÍÇÊ ÇáÞæáæä.

æÝí ÍÇá ßÇäÊ åäÇß ÖÑæÑÉ áÅÚØÇÁ ÇáãÑíÖ ÇáÚÞÇÑ¡ áÇÈÏ áå ÈÏÇíÉ Ãä íÚÇáÌ ÇáÞÑÍÉ æíÊÎáÕ ãäåÇ ÞÈá Ãä íÚØí ÇáãÑíÖ ÇáÓíáíÈÑíßÓ. æíãßä ÃíÖÇ ÅÚØÇÁ ÇáãÑíÖ ÇáÍãÇíÉ ÇáÖÑæÑíÉ ááãÚÏÉ ÞÈá æÕÝ ÇáÏæÇÁ áå.

Ýí ÇáãÓÊÞÈá íãßä ÇÓÊÎÏÇã ÇáÓíáíÈÑíßÓ ãÚ ãæÇÏ ÃÎÑì áÚáÇÌ ÃãÑÇÖ ÛíÑ ÇáÑæãÇÊíÒã ãËá ÚáÇÌ ÍÇáÇÊ ÓÑØÇäíÉ. æãä ÃÚÑÇÖ ÇÏæíÉ ÇáÜ (NSAIDs) ÇáäÒÝ ÇáÞÑÍí ááãÚÏÉ æÅáì ÙåæÑ ÓÍÌÇÊ ãä ÇáãÚÏÉ. æÈåÐå ÇáÔÇßáÉ íãßä Ãä íáÍÞ ÇáÖÑÑ ÈÇáãÚÏÉ.

ÇáßÈÏ

íÚÏ ÇáßÈÏ ÃßÈÑ ÛÏÉ ãæÌæÏÉ Ýí ÌÓã ÇáÅäÓÇä æÊÞæã ÈÊÕÝíÉ æÅÒÇáÉ ÇáãæÇÏ ÐÇÊ ÇáÓãÉ ÇáÓãíÉ. æÝí ßá ÇáÃÍæÇá ÝÅä Ãí ÏæÇÁ íÓÊÞáÈ Ýí ÇáßÈÏ æÊÌÑì áå ÚãáíÉ ÊÕÝíÉ. æÃãÇ ÈÇáäÓÈÉ ááÓíáíÈÑíßÓ ÝáíÓ áå Ãí ÊÃËíÑ íÐßÑ Úáì ÇáßÈÏ. íÚÑÝ ÇáÊåÇÈ ÇáßÈÏ ÇáÝíÑæÓí ÇáÃáÝí ÝäÓãíå ÇáæÈÇÆí ÃãÇ ÇáäæÚ ÇáËÇäí Ýåæ ÇáÇáÊåÇÈ ÇáÝíÑæÓí ÇáÈÇÆí¡ æíáÇÍÙ Ãä ÇáÇáÊåÇÈ ÇáßÈÏí ÇáæÈÇÆí åæ ÇáÃáÝí ÈíäãÇ íØáÞ Úáì ÇáäæÚ ÇáËÇáË ÇáÇáÊåÇÈ ÇáßÈÏ ÇáæÈÇÆí ÇáÌíäí (Óí).

íÓÇæí ÇáÊåÇÈ ÇáßÈÏ ÇáÝíÑæÓí ÇáÈí æÇáÓí ( ÇáÈÇÆí æÇáÌíãí) æåãÇ ÇáÊåÇÈÇä ãÒãäÇä Ýí ÇáßÈÏ.æÃãÇ ÇáÇáÊåÇÈ ÇáßÈÏí Èí æÓí ÝåãÇ áÇ íäÊÞáÇä Åáì ÇáÅäÓÇä ÅáÇ Úä ØÑíÞ äÞá ÇáÏã Ãæ Úä ØÑíÞ ÌÑÎ ãä ãÑíÖ áÔÎÕ ÛíÑ ãÕÇÈ Ãæ Úä ØÑíÞ ÇáããÇÑÓÇÊ ÇáÌäÓíÉ ÇáãÔÈæåÉ. æáßä áãÇÐÇ ÊÎÊÇÑ ÝíÑæÓÇÊ ÇáÇáÊåÇÈ ÇáßÈÏí Èí Ãæ Óí ÇáßÈÏ ÈÇáÊÍÏíÏ¡ ÇáãáÝÊ Ãä ßáíåãÇ íÎÊÇÑ ÇáßÈÏ áæáÚåãÇ ÈÇáäÓíÌ ÇáßÈÏí Ãæ ÇáÎáÇíÇ ÇáßÈÏíÉ æáßä ããßä Ãä íÕÈ ÇáãÑÖ ãäÇØÞ ÎÇÑÌ ÇáßÈÏ ßãÇ íãßä Ãä ÊÊÓÈÈ ÇáÅÕÇÈÉ Èå Åáì ÍÏæË ÇÖØÑÇÈÇÊ Ýí ÇáãÒÇÌ æíÊÚáÞ Ðáß ÈÕæÑÉ ÎÇÕÉ ÈÇáÇáÊåÇÈ ÇáßÈÏí Óí.

ÃãÇ ÈÔÃä ÚáÇÌ ÇáÇáÊåÇÈ ÇáÝíÑæÓí ÇáßÈÏí Óí ÝÞÏ Êã ÅÍÑÇÒ ÊÞÏãÇ ßÈíÑÇ Úáì ØÑíÞ ÇáÔÝÇÁ ÇáÐí ÈÇÊÊ äÓÈÊå ÊÊÑÇæÍ ãÇ Èíä 80 % æ85 % æÐáß Úä ØÑíÞ ÍÞä ÇáãÑíÖ ÈÅÈÑ ÊÄÎÐ ÃÓÈæÚíÇ æíØáÞ ÚáíåÇ ÇáÈíÌ ÅäÊÑÝíÑæä¡ æÝí ÍÇá ÇÓÊÎÏãåÇ ØÈíÈ ãÎÊÕ ÝáíÓÊ áåÇ ÃíÉ ãÖÇÚÝÇÊ.

- åá ÊÖÚÝ ÇáãËÈØÇÊ ÌåÇÒ ÇáãäÇÚÉ¿

Ü ÇáãåÏÆÇÊ áíÓÊ áåÇ ÃíÉ ÚáÇÞÉ ÈÇáÌåÇÒ ÇáãäÇÚí Ýí ÌÓã ÇáÅäÓÇä. æáÇ ÊÄËÑ ÞØ Úáì ÌåÇÒ ÇáãäÇÚÉ. æíÚÏ ÇáÅäÊÑÝíÑæä ãÇÏÉ ÊÞæí ÌåÇÒ ÇáãäÇÚÉ æãäÔØÉ áå. ÅäåÇ ÖÏ ÔíÁ ãÚíä¡ æåäÇß ÃäæÇÚ ãÊÚÏÏÉ ááÅäÊÑÝíÑæä ÇáÐí íÓÊÎÏã ÖÏ ÇáÇáÊåÇÈ ÇáßÈÏí ÇáÝíÑæÓí.

áíÓ åäÇß Ãí ÃÏæíÉ ÊÄËÑ Úáì ÇáÌåÇÒ ÇáãäÇÚí æÊÓÈÈ ÇÖØÑÇÈÇÊ áå æáÇ íÓÊØíÚ Úáì ÇáÏæÇã ÇáÊÏÎá Ýí ÇáÌíäæã Ãí ÇáÌíä ÇáæÑÇËí ÇáÎÇÕ ÈÇáÎáíÉ æáßä åäÇß ÃÏæíÉ ÊÊÓÈÈ Ýí ÊÞÑÍ ÇáãÚÏÉ æáßä áíÓ Úáì ÃÓÇÓ ãäÇÚí.

æåäÇ áÇ ÈÏ ãä ÇáÅíÖÇÍ ãä Ãä ÇáãÚÏÉ ãÍãíÉ ÈÛÔÇÁ ãÎÇØí æÇÞ æíæÌÏ ÊÍÊ ÇáÛÔÇÁ ÇáãÎÇØí ÎáÇíÇ ãÚíäÉ ÊÊÏÑÌ äÓÈÉ ÍãæÖÊåÇ æÈÚÏ Ðáß ÊÃÊí ÇáÎáíÉ ÇáÊí ÊÝÑÒ ÇáÈÑæÓÊÝáÇäÏíä ÇáÊí ÊÖÇÚÝ ÅÝÑÇÒ ÇáãÇÏÉ ÇáãÎÇØíÉ. æÇáãáÇÍÙ Ãä ÃÏæíÉ ÇáÇÓÊíÑæÆíÏÇÊ ÓæÇÁ ÇáÞÏíãÉ Ãã ÇáÍÏíËÉ ÊÄËÑ Úáì ÇáãÚÏÉ áÃäåÇ ÊÄËÑ Úáì ÅÝÑÇÒÇÊ ÇáÈÑæÓÊÛáÇäÏíä.

æáÃä ÇáÈÑæÓÊÛáÇäÏíä íÝÑÒ Úä ØÑíÞ ÇáÜ COX-2 ÝÅä ÇÓÊÎÏÇã ÇáÃÏæíÉ ÇáãåÏÆÉ íÄÏí Åáì ÊËÈíØåÇ. æáÐáß ÝÅääÇ ÚäÏãÇ äÚØí ÔÎÕÇ ãËá åÐå ÇáÃÏæíÉ íäÈÛí ÈÏÇíÉ Ãä äÑÇÚí ãÇ ÅÐÇ ßÇä ãÕÇÈÇ ÈÇÖØÑÇÈÇÊ Ýí ÛÔÇÁ ÇáãÚÏÉ. æåäÇß ÇáÂä ÇÊÌÇå ÚÇáãí íÏÚæ ááÊÃßÏ ãä ÍãÇíÉ ÇáãÚÏÉ ÞÈá ÊÞÏíã Ãí ÚáÇÌ ãËÈØ. æÊÓÊÎÏã ÍÇáíÇ áÊÍÞíÞ Ðáß ÃÏæíÉ ÇáÜ «Èí Èí Âí» ãËá ÈÇÑíæÊ æÈäßÈÑÒæá¡ æåí ÃÏæíÉ ÌíÏÉ ÌÏÇ áÍãÇíÉ ÇáãÚÏÉ ÎÕæÕÇ ÈÚÏ ÇáÇÓÊÚãÇá ÇáãÒãä áÃÏæíÉ ÇáÃäÓíÏ æãÖÇÏÇÊ ÇáÇáÊåÇÈÇÊ ÛíÑ ÇáÓíÑæíÆÏíÉ ÇáÍÏíËÉ. æÈÇáØÈÚ ÝÅä ÚáíäÇ Ãä äÓÊÎÏã ÃÏæíÉ ÍãÇíÉ ááãÚÏÉ ÃßËÑ Ýí ÍÇá ÇÓÊÎÏÇã ÇáÃÌíÇá ÇáÞÏíãÉ ááÅÓíÑæíÆÏÇÊ.

ÏÇÆãÇ ÃäÕÍ ÇáãÑÖì æÇáäÇÓ ÌãíÚÇ ÈÊÌäÈ ÇáÍÕæá Úáì ÇáÚÞÇÞíÑ ÇáØÈíÉ ãä ÇáÕíÏáí ãÈÇÔÑÉ ÞÈá ãÑÇÌÚÉ ÇáØÈíÈ. æÊÌäÈ ÇÓÊÎÏÇã ÇáÏæÇÁ ÈäÇÁ Úáì ÇáäÕÇÆÍ ÇáÚÔæÇÆíÉ ááÒãáÇÁ æÇáÃÞÇÑÈ Ãæ ÇáÌíÑÇä¡ ÝáÇÈÏ ÞÈá ßá ÔíÁ ãä ãÑÇÌÚÉ ÇáØÈíÈ ÇáãÎÊÕ ÇáÐí íÚáã ÊãÇãÇ Ãí ÏæÇÁ íÍÊÇÌå ãÑÖß æÍÇáÊß ÇáãÑÖíÉ. æÈåÐå ÇáÕæÑÉ íãßä Ãä ÊäÌæ ãä ÃíÉ ãÖÇÚÝÇÊ.

æåäÇß ãä ÑÇÌÚäí ãä ÇáãÑÖì ÈÚÏ Ãä ÊäÇæá ÃÏæíÉ ãåÏÆÉ æÍÏË äÒíÝ áå Úä ØÑíÞ ÝÊÍÉ ÇáÔÑÌ. æÈÇÊ áæä ÎÑæÌå ÃÓæÏ¡ æÞãäÇ ÈÚãáíÉ ÊäÙíÑ áå æÇßÊÔÝäÇ æÌæÏ ÌÑæÍ Ýí ãÚÏÊå. æåäÇß ÇáßËíÑ ãä ÇáÍÇáÇÊ ÇáÊí ÊÒæÑäí Ýí ÚíÇÏÊí íÚÇäí ÃÕÍÇÈåÇ ãä ãÖÇÚÝÇÊ ãÚÏíÉ ÈÚÏ ÊäÇæá ÇáÃÏæíÉ ÇáãÓßäÉ Ïæä ãÑÇÌÚÉ ÇáØÈíÈ.

æãÇ íÌåáå ÇáãÑíÖ Ãäå ÚäÏãÇ íÑÛÈ Ýí ÊæÝíÑ ÈÖÚÉ ÏÑÇåã ÚäÏãÇ íÔÊÑí ÇáÏæÇÁ ãÈÇÔÑÉ ãä ÇáÕíÏáí ÝÅäå íÎÇØÑ ÃæáÇ ÈÍíÇÊå æÞÏ íÊÚÑÖ áÊÏÇÚíÇÊ ÎØíÑÉ æÞÏ íÖØÑ Ýí ÇáäåÇíÉ áãÑÇÌÚÉ ÇáØÈíÈ Ýí ÍÇá ÇáãÖÇÚÝÇÊ¡ æáÏÝÚ ãÈÇáÛ ØÇÆáÉ áÚáÇÌ ÃãÑÇÖ áã Êßä ãæÌæÏÉ Ýí ÇáÃÕá.

ãäÐ ÇáÈÏÇíÉ ääÕÍ ÇáãÑíÖ ÈÇáÊæÌå Åáì ÇáØÈíÈ ÇáãÎÊÕ ÇáÐí íØáÈ ãäå ÈÏÇíÉ áÚãá ÊÍÇáíá áÊÍÏíÏ ÇáÅÕÇÈÉ ÊãåíÏÇ áæÕÝ ÇáÏæÇÁ ÇáãäÇÓÈ æÊßæä ÈåÐå ÇáÕæÑÉ ÇÍÊãÇáÇÊ ÔÝÇÆå ÞæíÉ ÈÚíÏÇ Úä ÇáãÛÇãÑÉ æÇáãÎÇØÑÉ.ßãÇ Ãä ÇáäÝÞÇÊ ÇáØÈíÉ Êßæä ÞáíáÉ ÌÏÇ ÞíÇÓÇ ÈãÇ ÓíÏÝÚå ÈÚÏ ÇÓÊÝÍÇá ÇáÃÚÑÇÖ ÇáÌÇäÈíÉ áÇÓÊÎÏÇã Ãí ÏæÇÁ. æíÚäí Ðáß Ãä ÇáÒíÇÑÉ ÇáÊí íÞæã ÈåÇ ÇáãÑíÖ áÚíÇÏÉ ÇáØÈíÈ æÇáäÞæÏ ÇáÊí ÓíÏÝÚåÇ ÊÚÇÏá ËãäåÇ. æáÇ íÚäí Ãä ÇáãÑíÖ ÈåÐå ÇáÕæÑÉ ÓíáÞí ÈäÝÓå Ýí ãåÈ ÇáãÑíÍ.

ÇáÃãÑÇÖ ÇáãÚæíÉ

áÇ ÊæÌÏ ÃãÑÇÖ ãÓÊæØäÉ Ýí ãäØÞÊäÇ ÍíË áÇ ÊæÌÏ ãÓÊäÞÚÇÊ¡ æÇáÃãÑÇÖ ÇáãÓÊæØäÉ ÊæÌÏ Úáì ÇáÃÛáÈ Ýí ÇáÈáÏÇä ÇáÊí ÊæÌÏ ÝíåÇ ãÓÊäÞÚÇÊ æØÝíáíÇÊ æíÚÏ ÇáÈÚæÖ äÇÞáÇ áåÇ. æÇáÍÞíÞÉ ÝÅä ÅÕÇÈÇÊ ÇáßÈÏ ÇáÝíÑæÓíÉ ßÇãäÉ Ýí ÇáÅãÇÑÇÊ æáßä áÇÈÏ áßá ÅäÓÇä ãä ÒíÇÑÉ ÚíÇÏÉ ÇáØÈíÈ ÍÊì íØãÆä ãä Ãäå ÛíÑ ãÕÇÈ ÈÝíÑæÓ ÇáÇáÊåÇÈ ÇáæÈÇÆí ÇáßÈÏí. æíäÈÛí ÒíÇÑÉ ÇÎÊÕÇÕí ÇáßÈÏ áÅÌÑÇÁ ÇáÝÍæÕÇÊ ÇááÇÒãÉ Èíä ÇáÍíä æÇáÃÎÑ.

äÞá ÇáÏã

äÞá ÇáÏã Ýí ÏæáÉ ÇáÅãÇÑÇÊ Âãä ãäÐ 15 ÚÇãÇ Úáì ÅËÑ ÇßÊÔÇÝ ÇáÝíÑæÓ (Óí). æÎÕÕÊ ÃÌåÒÉ Ýí ÇáãÓÊÔÝíÇÊ ááßÔÝ Úáì æÍÏÇÊ ÇáÏã æÇáÊÃßÏ ãä ÚÏã ÊáæËåÇ ÞÈá äÞáåÇ ááãÑíÖ.

«ÓíáíÈÑíßÓ»

íÞáá ÇÍÊãÇáÇÊ ÇáÅÕÇÈÉ ÈÓÑØÇä ÇáËÏí

äÔÑÊ ÕÍíÉ ÇáÊÇíãÒ ÇááäÏäíÉ ÏÑÇÓÉ ÌÏíÏÉ ÃÔÇÑÊ Åáì Ãä ÃÍÏË ÈÍË Úáì ÚÞÇÑ Celebrex ÊæÕá Åáì Ãä ÇáäÓÇÁ ÇááÇÊí ÊäÇæáä ÇáÚÞÇÑ Úáì ãÏì ÚÇãíä ÊÑÇÌÚÊ áÏíåä ÇÍÊãÇáÇÊ ÇáÅÕÇÈÉ ÈÓÑØÇä ÇáËÏí ÈäÓÈÉ 71%.

æÃÔÇÑÊ ÇáÏÑÇÓÉ Åáì Ãä ÇáäÓÇÁ ÇááÇÊí ßä íÊäÇæáä ÌÑÚÉ ãä ÇáÓáíÈÑíßÓ ãÞÏÇÑåÇ 200 ãááíÌÑÇã Ýí Çáíæã¡ æåí ÌÑÚÉ ØÈíÚíÉ ÈÇáäÓÈÉ áÃí ÔÎÕ ãÕÇÈ ÈÃáã ÇáÊåÇÈ ÇáãÝÇÕá ÊÑÇÌÚÊ áÏíåä ãÎÇØÑ ÇáÅÕÇÈÉ ÈÓÑØÇä ÇáËÏí ÈäÓÈÉ 83%. æåäÇß ÝÑÕÉ áÊÞáíá ÇÍÊãÇá ÅÕÇÈÉ äÓÇÁ ØÇÚäÇÊ Ýí ÇáÓä ÈãÑÖ ÓÑØÇä ÇáËÏí Ýí ÍÇá ÍÕáä Úáì æÕÝÇÊ ØÈíÉ ÊÍÊæí Úáì ÇáÚÞÇÑ



ÇáãÜ ÕÜ ÏÑ (http://albayan.ae/servlet/Satellite?cid=1139465670374&pagename=Albayan%2FArticle%2FFullDetail&c=Article)


ãÚ ÇáÔßÑ æ ÇáÊÞÏíÑ áÃÎí ÃÍãÏ Úáì ÍÑÕå

æ ÏÇÆãÇð äÍÐÑ ãä ÇáÇÓÊÎÏÇã ÇáÎÇØÆ ááÏæÇÁ ( Ãí ÏæÇÁ ) æ Ãä áÇ íÄÎÐ ÇáÇ ÊÍÊ ÅÔÑÇÝ ØÈíÈ

ãÍãÏ ÇáÑãæËí
09-15-2006, 02:12 AM
بارك الله فيك على هذا التنويه